Vimarsana
Biggest News Aggregation in the World

Interim Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Interim Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Interim Data Today - Breaking & Trending Today

Immunic to Participate in Investor and Scientific Conferences in May - Vimarsana News

Immunic to Participate in Investor and Scientific Conferences in May

NEW YORK, May 6, 2024 /PRNewswire/ -- Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and...

Molecular Templates Presents Interim Data from MT-6402 - Vimarsana News

Molecular Templates Presents Interim Data from MT-6402

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies - Vimarsana News

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. a commercial-stage, cancer...

Larimar Therapeutics Inc (LRMR) Reports Q3 2023 Financial Results and Clinical Progress - Vimarsana News

Larimar Therapeutics Inc (LRMR) Reports Q3 2023 Financial Results and Clinical Progress

Key Developments in FA Treatment Trials and Financial Position Strengthening

Source: yahoo.com
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results - Vimarsana News

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

U.S. Food and Drug Administration Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia Collaboration with Eli Lilly and Company ...